To assess the effect of prolonged administration of midazolam or isoflurane on hepatocellular integrity,we measured the concentrations of glutathione transferase (EC 2.5.1.18) B1 subunit and the activities of alanine aminotransferase (ALT; EC 2.6.1.2) and aspartate aminotransferase (AST; EC 2.6.1.1) in 40 patientswho required long-term sedation with low-dose midazolam or isoflurane. Blood samples were collected before and 24 h after the start of the sedation and 0, 24, 72, 120, and 172 h after the last dose. ALT and AST activities did not change appreciably, but the glutathione transferase B1 concentration decreased significantly (P <0.03) at all times studied. The patients who received isoflurane and those who received midazolam showed no significant differences in any of the enzyme tests. We conclude that long-term sedation with midazolam or isoflurane is unlikely to affect hepatocellular integrity.
Volatile anesthetics, especially halothane, can produce hepatic damage (1, 2) . Although the mechanism by which this rare but severe cause of fulminant hepatic failure occurs is unknown, prolonged administration of such anesthetics is a risk factor. Emergency admissions to intensive therapy units often require prolonged sedation with various agents. Midazolam, a short-acting benzodiazepine, is commonly used for sedation in intensive-care units; more recently, isoflurane (a fluorinated inhalational agent widely used in general anesthesia) has been used with ventilated patients in intensive therapy units (3) . Although some studies have examined the effects of single doses of midazolam (4) and isoflurane (5) , the possible effects of long-term administration of these drugs on liver integrity have not been described.
Serum or plasma concentrations of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are commonly used to assess hepatic injury.3 ' However, because the aminotransferases are not specific to the liver and can be released under other conditions, it is often difficult to ascribe small abnormalities in their plasma activities to hepatic damage. In addition, the aininotransferases, which are found mainly in periportal hepatocytes (6), are relatively insensitive markers of damage to centrilobular hepatocytes, the cells most prone to damage by halothane, alcohol, toxins, and hypoxia.
The glutathione transferases are a family of dimeric detoxification proteins that catalyze the conjugation of glutathione with a wide spectrum of electrophiles (7) . For many reasons, the measurement of one of the glutathione transferase subunits, glutathione transferase B1 (GST B1), by radioimmunoassay (RIA) is considered advantageous over aminotransferase measurements in investigating hepatic damage (8) . linmunohistochemical studies of the hepatic distribution of GST B1 in adult human liver showed that GST B1 is uniformly distributed across the entire liver lobule (9); thus, damage to any zone of the liver results in release of GST B1 into plasma. The high concentration of (1ST B1 in human liver cytosol [-3% of the total cytosolic protein (10) ] and its low molecular mass (52 kDa) contribute to its being readily released in quantity into the circulation after hepatic damage. Moreover, the short half-life of GST B1 in plasma (<1 h) means that, after the damage has ceased, its plasma concentration quickly reverts to normal. These factors together with the high organ specificity of GST B1 to liver (11) make it a sensitive plasma marker of liver integrity.
Here we examined the effect of prolonged administration of isoflurane or midazolam on plasma ALT, AST, and (1ST B1 activity concentrations to assess what effect these two agents have on hepatocellular integrity.
Subjects and Methods
Patients. We studied 40 patients admitted to an intensive therapy unit who required sedation after various surgical procedures or medical emergencies. The patients were randomly allocated to treatment groups and received either subanesthetic doses of isoflurane (1-6 mLIL) or a continuous intravenous infusion of midazolam (0.01-0.2 mg kg' . h'). Table 1 outlines details for patients in each group, and Table 2 lists reasons for admission. About 80% of the patients in both groups had been anesthetized before admission, but none had received halothane. Blood samples were taken into lith- (Table 1) ; therefore, the time 0 poatsedation specimen represents the effects of various sedation periods. Plasma was obtained by centri#{241}igation at 2500 X g for 15 miii.
Methods. AST and ALT in plasma were measured on the day of collection by using a Boehringer Mannheim/ Hitachi 717 clinical chemistry analyzer, with no pyridoxal 5'-phosphate added to the reaction mixture (Boshringer Mannheim UK, Lewes, Sussex, U.K.). A portion of plasma was stored at -20 #{176}C for subsequent analysis of GST B1 concentration by RIA as previously described (12) . All assays had between-batch CVs of <8%. pressed as multiples of the upper reference limit) were correlated.
Resufts
The two groups were closely matched for age, weight, sex, duration of sedation, number previously anesthetized, and number of fatal outcomes (Table 1 ). Figure 1 illustrates the mean ± SE, at the various times, for plasma activities of AST, ALT, and (1ST B1 for the patients who received either isoflurane or midazolam sedation. Comparison between these two groups of patients showed no significant differences in any of the enzyme tests at any of the times. Enzyme activities after sedation ceased (time 0 postsedation) in patients who received sedation for <37 h vs patients who received sedation for 37 h showed no significant differences for AST, ALT, or GST B1.
No significant differences were recorded between the two groups for any of the enzymes measured on admission to the intensive therapy unit. The mean admission activities (time 0 sedation) for AST, ALT, and GST B1, respectively, were 1.7, 0.9, and 9.3 times the upper reference limit for the midazolam group and 1.7, 0.8, and 6.0 times the upper reference limit for the isoflurane group. On admission, 12, 7, and 16 patients in the midazolam group and 13, 4, and 15 patients in the isofiurane group had increased AST, ALT, and GST B1 activities, respectively.
No significant changes occurred during the study for ALT or AST, but the GST B1 activity significantly decreased (midazolam patients P <0.01; isoflurane patients P <0.03) between the admission sample and samples obtained at all the other times. No other differences were found. The apparent increase in GST B1 concentration between 24 and 120 h (Figure ic) for both groups failed to reach significance (P <0.12 andP <0.08 for the midazolam and isofiurane groups, respectively).
Pearson's correlation coefficients for the different enzymes at time 0 sedation and for the mean of enzyme concentrations postsedation are given in Table 3 . All correlations improved for the mean of the postsedation samples compared with the time 0 samples.
DIscussIon
This study suggests that prolonged administration of either isofiurane or midazolam for sedation has no detrimental effects on hepatocellular integrity. We were unable to demonstrate any increase in any of the three enzymes measured at any time after administration of either of the agents or in the 172 h after sedation was withdrawn. Nine patients had abnormal GST B1 concentrations at the conclusion of the study, but all also had increased GST B1 concentrations on admission. We showed previously that administration of isofiurane at anesthetic doses for a short time produced no significant changes in plasma (1ST B1 or ALT, whereas halothane produced an increase in plasma GST B1 in -10% of patients 24 h after exposure (13) . The present data suggest that isoflurane or midazolam can be used for prolonged sedation without risk of producing hepatic damage in most patients.
Although the correlation between the activities of each of the enzymes studied in samples obtained on admission was significant, the significance increased for the postsedation samples. At admission, the plasma concentration of GST B1 was markedly increased in 78% of the patients, whereas ALT and AST activities were normal or only modestly increased. These observations are consistent with previous observations of GST B1 and amunotransferase concentrations in hypoxia (14), hypoglycemia (15) , impaired hepatic blood flow (13) , and early acetamunophen poisoning (16) , where GST B1 activities were increased even when aminotransferase activities were normal. The discrepancies between annnotransferase and (1ST B1 results can be explained by each of the aforementioned conditions affecting predominantly centrilobular hepatocytes rather than the cells in the periportal zone of the liver. The present results are also consistent with impaired centrilobular hepatocellular integrity in the majority of patients admitted to an intensive therapy unit. This is expected because most patients had been subjected to major surgery or other conditions expected to lead to impaired hepatic perfusion or hepatic hypoxia; this, in turn, would affect centrilobular hepatocytes more than periportal cells. The data also show that the centrilobular cells can rapidly recover from an acute insult, as illustrated by the rapid decrease in plasma GST B1 concentrations in the 24 h after admission (Figure 1) .
The increased activities of AST (-1.7 times the upper reference value) recorded throughout the study may occur because it is the least specific of the enzymes measured. AST values were increased at admission but ALT values were not. Because both these transamunases have similar sensitivities for reflecting acute liver damage, then presumably the AST in plasma is of nonhepatic origin. High concentrations of AST are also found in heart, skeletal muscle, kidney, and pancreas. Many of the patients had undergone surgery or trauma; thus, damage to muscle might explain the increased AST values in the presence of normal ALT activities.
This study shows that plasma GST B1concentrations must be interpreted with caution when used to investigate patients with suspected chronic or acute liver disease. Of the patients admitted to our intensive therapy unit, only one had chronic liver disease, but 80% had increased GST B1. The sensitivity of (1ST B1 mea-surements for detecting even mild liver dysfunction means that a high proportion of patients with acute cardiorespiratory failure, left ventricular failure, or multiple trauma or patients after major surgery may have markedly increased plasma (1ST B1 concentrations but also that these abnormalities will rapidly return to normal when normal liver perfusion and oxygenation are restored.
